Germany · Delayed Price · Currency is EUR Oryzon Genomics Company Description
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders.
Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases.
Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others.
The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
| Country | Spain |
| Founded | 2000 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 47 |
| CEO | Carlos Manuel Arjol |
Contact Details
Address: Sant Ferran 74 Cornellà de Llobregat, 08940 Spain | |
| Phone | 34 93 515 13 13 |
| Website | oryzon.com |
Stock Details
| Ticker Symbol | ORN |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Carlos Manuel Arjol | Chief Executive Officer |
| Enric Condomines | Chief Financial Officer |
| Enric Condomines | Chief Operating Officer |